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ABSTRACT: Introduction: We assessed proficiency (accuracy and
intra- and intertest reproducibility) of smart quantitative sensation
tests (smart QSTs) in subjects without and with diabetic sensorimo-
tor polyneuropathy (DSPN). Methods: Technologists from 3 medical
centers using different but identical QSTs independently assessed 6
modalities of sensation of the foot (or leg) twice in patients without
(n5 6) and with (n5 6) DSPN using smart computer assisted
QSTs. Results: Low rates of test abnormalities were observed in
health and high rates in DSPN. Very high intraclass correlations
were obtained between continuous measures of QSTs and neurop-
athy signs, symptoms, or nerve conductions (NCs). No significant
intra- or intertest differences were observed. Conclusions: These
results provide proof of concept that smart QSTs provide accurate
assessment of sensation loss without intra- or intertest differences
useful for multicenter trials. Smart technology makes possible effi-
cient testing of body surface area sensation loss in symmetric
length-dependent sensorimotor polyneuropathies.
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Loss of sensation is a common manifestation of
various sensory and sensorimotor polyneuropa-
thies.1–5 These polyneuropathies are common and
of diverse cause: metabolic alterations (diabetes
mellitus, uremia, and others); infections (HIV,
herpes, leprosy, syphilis, Lyme borreliosis, and
others); malnutrition, vitamin deficiency, and
alcoholism; intoxications (medicinal and indus-
trial); inflammatory immune conditions; genetic
causes and others. Detection, characterization and
quantification of the kind, distribution, and sever-
ity of sensation loss and of heightened sensory
phenomena (positive neuropathic sensory symp-
toms and tactile and thermal hyperalgesia) are
useful for detection, differential diagnosis, and
follow-up of these diseases.6–8 Following the course
of sensation loss over time may be needed in thera-
peutic trials and in monitoring effectiveness of
therapy of patients on treatment regimens. Increas-
ingly, quantitative sensation tests (QSTs) are being
used in therapeutic trials, e.g., in diabetic sensori-
motor polyneuropathy (DSPN), transthyretin
Abbreviations: ATTR-PN, transthyretin amyloid polyneuropathy; CASE
IVb and c, a design by PJD and colleagues, Computer Assisted Sensory
Examination – the version marketed by WR Medical Electronics, Maple-
wood, called Computer Aided Sensory Evaluator.; C disc, cooling discrimi-
nation using Dyck thermal disks; CDT, cooling detection threshold; DM,
diabetes mellitus; DSPN, diabetic sensorimotor polyneuropathy; HP 0.5,
heat-as-pain detection threshold; HP 5, an intermediate threshold level of
heat-as-pain severity from 1–10; Nds, normal deviates from percentiles;
NIS, Neuropathy Impairment Score; NSC, Neuropathy Symptoms and
Change Score; QSTs, quantitative sensation tests; “smart” QSTs, smart
quantitative sensation tests; TP DT, touch-pressure detection threshold;
VDT, vibratory detection threshold
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amyloid polyneuropathy (ATTR-PN), and Fabry
disease.6,9,10
This study focuses on the performance of spe-
cific smart QSTs that are being used increasingly
in therapeutic trials. These QSTs are computer
controlled (smart), standardized, and referenced.
They provide printed test results of what was done
and found, and results are compared with refer-
ence values. They are tests of both large and small
sensory fiber functions. Because of these design
features, it is assumed that they can provide accu-
rate information about sensory loss, which should
be the same among participating medical centers
and over time. However, this assumption, although
reasonable, must actually be tested in field studies,
which is the purpose of this trial. It might be
argued that improved assessment of sensation
using smart QSTs is not needed, because better
assessments can be done by expert physicians.
However, this assumption must now be questioned,
because it has been shown that even evaluations by
expert neuromuscular physicians were not as accu-
rate and reproducible as had been assumed.11,12
However, expert neuromuscular physician per-
formance could be improved markedly by consen-
sus development and the use of the simple
criterion of judging only unequivocal abnormality
while taking age, gender, and physical fitness into
account.11,12 Therefore, to obtain proficient physi-
cian examinations, considerable selection, training,
and surveillance of physician performance is neces-
sary. Therefore if some evaluations done by physi-
cians could be performed by trained technologists
using smart QSTs, therapeutic trials might be per-
formed more efficiently and accurately.
In this trial (Cl vs. NPhys Trial 5), we assess not
only the accuracy but also the intra- and intertest
reproducibility of 6 highly standardized and refer-
enced QSTs administered by technologists from 3
different medical centers in the same masked
patients without and with DSPN.
RESEARCH DESIGN AND METHODS
Trial Context. Previous studies in this series of clin-
ical versus neurophysiology tests have evaluated
the proficiency of the clinical assessment of signs
and symptoms (Trials 1 and 2)11,12; attributes of
nerve conduction (Trials 313 and 4 [being pre-
pared for publication]); and in this trial (Trial 5)
of smart QSTs in DSPN. Considerable attention
had been given at an earlier time to making all
aspects of QST as standard, automated, referenced,
and efficient as possible to limit the role of the
technologist to ensuring highly standardized
instruction and testing. This standardization was
intended to obtain test result reproducibility
among medical centers and over time.
Smart Quantitative Sensation Tests (“Smart”
QSTs). By “smart” QST, we refer to use of special
technologies (instruments), computer software, and
standard test conditions to make QST as standard,
reproducible, referenced, automated, and efficient
as possible so that trained technologists, under the
supervision of an expert physician, can assess cuta-
neous sensation accurately and reproducibly at pre-
determined anatomical sites as proficiently as
possible. In “smart” QST, all aspects of sensation
evaluation (i.e., instruction of subjects, stimuli used,
algorithms of testing and finding threshold, com-
parison to reference values, and printout of what
was done and observed) should be standard, quanti-
tated, described in detail, and validated in the scien-
tific literature. A final report should be generated
which summarizes patient and evaluator informa-
tion, all stimuli given, choices made, estimated
threshold, and comparison to reference values.
In this trial, we tested both hand- and
instrument-administered stimuli and both large
and small sensory fiber functions. For hand-
administered stimuli of large fiber function, we
assessed touch-pressure threshold using 9 graded
monofilaments and small fiber function using
Dyck thermal disks. For instrument-administered
stimuli of large fiber function we assessed vibra-
tion, and for small fiber function we assessed cool-
ing and heat as pain (CASE IVc, WR Medical
Electronics, Maplewood, MN) sensations.
Monofilament testing of touch pressure thresh-
old was performed with Semmes Weinstein mono-
filaments that were modified by us so that
monofilaments A, B, C - - - I produced static loads
of 23, 22, 21 - - - 5 ln gms at 5/6 of their
extended lengths.8 Nineteen magnitudes of touch-
pressure can be tested using this approach.8 We
used a slightly modified, previously described, algo-
rithm of forced-choice 2:1 stepping to assess touch-
pressure threshold.8 The procedure of testing was
demonstrated to technologists by a video presenta-
tion and also in a short training session lasting 3
to 4 h before the formal trial described below. To
provide highly standardized hand-held testing the
technique of application of the monofilament is
described here in detail and illustrated in Figure 1.
Application of the monofilament is at right
angles to the surface of the skin. The tip of the
monofilament is brought to within 1 or 2 mm of
the skin surface, gently lowered to make skin con-
tact, then depressed further to bend the monofila-
ment to 5/6 of its extended length, then slowly
released. The entire sequence, from contact to
breaking of contact, should take 1.5–2 s and be
done smoothly. For null stimuli, the technologist
performs a sham movement without actually mak-
ing contact with the skin. Testing is done with the
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subject’s eyes closed or with use of a blindfold if
needed. The patient must say whether he/she was
touched during periods 1 or 2 (the random
sequence provided by the computer program); the
examiner says “1” then “2” for the 2 intervals of
forced-choice testing.
Cooling discrimination (C disc) was tested with
Dyck Thermal Disks (described previously, Fig. 1).14,15
Thermal disks have standard dimensions, weights,
and appearances (except for the identification nota-
tion on the end of the handle not visible to subjects
or patients. The different test thermodes have differ-
ent heat transfer characteristics based on different
material on their surfaces. A standard 2:1 forced-
choice stepping algorithm was used to determine
threshold with initial published reference values.15
The algorithm of testing and reference values
corrected for anatomical sites and applicable varia-
bles was provided by us but programmed for perso-
nal computer and the CASE IV instrument (WR
Medical Electronics, Maplewood, MN).
Vibratory detection threshold (VDT), CDT, and
HP 0.5 and an intermediate severity of heat pain
(HP 5) were evaluated using CASE IVc (initially
developed by us16 and later manufactured by WR
Medical Electronics, Maplewood, MN but without
our proprietary involvement; see author disclo-
sure). The 4, 2, and 1 stepping algorithm with null
stimuli was used to determine VDT and CDT.7 For
assessment of HP 5 (intensity 5 of 1–10), an
ascending nonrepeating stepping algorithm with
null stimuli was used.7 The number of stimuli and
null stimuli used in CASE IV testing has been
described previously and is standard.7 In forced-
choice testing of touch pressure and cooling dis-
crimination, the numbers of pairs of stimuli and
null stimuli are variable depending on age, thresh-
old of sensation, and performance of subjects.8,15
Typically, technologists could perform the
6 QSTs within the allotted time period of 1 h and
20 min. Approximately half of the time was spent
in setting up the tests and providing instruction.
Tests like vibratory and touch-pressure may be done
in 3 to 6 min, whereas estimation of HP 0.5 and
HP 5 may take a somewhat longer period of time.
Training of QST Technologists. Three technologists
from different medical centers (Baltimore, MD
[B.A.], Ann Arbor, MI [S.N.], and Rochester, MN
[L.G.]) performed the QST. All had training and
FIGURE 1. Features of Smart QST. A,B: Monofilament testing is illustrated. C: Testing with Dyck thermal disks is shown. D: In vibra-
tory sensation testing with CASE IVc, vibratory stimuli are superimposed on a static load to allow eloquent and quantitative control of
stimuli and null stimuli. E: The standard thermode in place on the foot to test cooling and heat-as-pain thresholds. Standard thermal
pulses are superimposed on a small offset from skin temperature to assess modalities of thermal sensation. The restraining strap
must be tightened just to the point at which the thermode makes full contact with the skin.
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experience with QST, but only 1 (L.G.) performed
QST regularly. The 2 neurophysiology technolo-
gists who performed QST infrequently (B.A. and
S.N.) were sent instructional material, a training
video, sets of monofilaments and thermal disks,
and the personal computer programs (provided by
WR Medical Electronics, Maplewood, MN) for
monofilament and thermal disk testing.
On the day preceding the 4-day trial at Rochester,
MN, the standard testing procedures were reviewed
for 3 to 4 h, demonstrated, and practiced on
healthy subjects. The emphases in this brief training
session were: (1) use of standard assessments, (2) use
of the same verbal instruction using cueing cards, (3)
standard application of stimuli at standard anatomical
sites, (4) need to keep the subject attentive, (5) cor-
rect performance of standardized testing and enter-
ing of responses, and (6) final printing out of test
results.
Selection of Trial Subjects. Twelve subjects, 6
healthy and 6 persons with DSPN, were recruited
for study from the Rochester Diabetic Neuropathy
Study of healthy subjects17 and patients with DM.3
The neuropathy status was assessed after obtaining
consent for the study by determining attributes of
nerve conduction and performance of the Neurop-
athy Impairment Score. Subjects signed informed
consent approved by the Mayo Clinic Institutional
Review Board and were paid an honorarium to off-
set time away from other activities.
Conduct of Cl Versus NPhys Proficiency Trial 5 (the
Present Trial). To keep research costs low, the 2
technologists from Maryland and Michigan per-
formed studies on 12 subjects at Rochester, MN,
rather than have the 12 subjects travel to those
medical centers. The studies were performed on
December 6–9, 2011, in the QST Laboratory at
Mayo Clinic, Rochester, MN. Arrangements were
made to have completely independent QST assess-
ments of the 12 subjects by each technologist on 2
occasions. Three different QST CASE IVc instru-
ments and hand-held testing devices were used by
the 3 technologists. Technologists were asked to
not obtain subject or disease information during
QST. The order of QST was randomized so that 3
subjects were evaluated concurrently for all 6
modalities of sensation by each of the 3 technolo-
gists in a half day period (54 QSTs). Approxi-
mately 80 minutes was made available for
performance of the 6 QSTs. The tests were
repeated, in random order, on the third or fourth
day (a total of 432 QSTs). In each testing session,
the order of tests followed by each technologist
was: TP DT, C disc, VDT, CDT, and HP 0.5, and
HP 5.0. Immediately after each QST session, auto-
mated printed results were handed to supervisory
study personnel without revision or alteration.
Testing was done on the dorsum of the left
foot of all subjects except for the heat pain test,
which was done on contiguous regions of the lat-
eral leg to avoid a change in threshold due to
repeat testing and to avoid possible thermal injury.
Monofilament testing was done on the dorsal ter-
minal phalanges of all 5 toes. Vibratory testing was
done on the dorsal surface of the terminal phalanx
of the first toe. Cooling threshold was tested on
the flat dorsal surface overlying the distal half of
the metatarsal bones (Fig. 1).
Results of QSTs were compared with standard
neurologic assessment of signs (Neuropathy
Impairment Score [NIS]), symptoms (Neuropathy
Symptoms and Change [NSC]) and a composite
score of attributes of nerve conduction (R5 NC
nds 2.5th percentile).17–19
Analysis. Standard statistical tests were used to
assess accuracy and intra- and interobserver differ-
ences (see Tables (1–3)). The ICC in Table 2 was
calculated using a two-way mixed effects model
with each measurement obtained from 1 individ-
ual.20 Because QST, NIS, NSC, and R5 NCs were
measured by different scales, they were standar-
dized before calculating the ICC.
RESULTS
The Frequency of QST Abnormalities. The raw val-
ues of QSTs and comparative neuropathy tests
(NIS, NSC, and R5 NCs) values are shown in Table
1. None of the healthy subjects (1–6) had abnor-
mality of signs (NIS), symptoms (NSC), or nerve
conduction (R5 NCs) assessed by masked evalua-
tion (Table 1). Of the 6 healthy subjects only sub-
ject 2 had a QST abnormality; the mean value of
VDT was in the abnormal range (i.e., 97.5th per-
centile). Because VDT in patient 2 was abnormal
in 4 of 6 individual evaluations and almost abnor-
mal in the remaining 2, it is likely that this patient
has an abnormality of VDT of the great toe (for
reasons not determined) despite not having signs,
symptoms, or NC abnormalities. None of the mean
values of the other QST modalities were abnormal
in this subject. A few additional QST abnormalities
of individual tests were found in other healthy sub-
jects and in the following frequencies: monofila-
ment 0/36, CDT 3/36, cooling discrimination
0/36, HP5 0/36, and HP 0.5 2/36. For the entire
healthy subject group, QST abnormalities were
observed in 9 of 216 QSTs (i.e., in 4%), close to
the 2.5% we had set as a rigorous level of test
abnormalities. If patient 2 is considered to actually
have a VDT abnormality of the tested great toe,
the frequency of QST abnormalities in healthy sub-
jects falls below the 2.5 percentage level.
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Of the 6 patients with DSPN (patients 7–12 in
Table 1), mean values of QSTs were abnormal in
the following frequencies: VDT 6/6; monofilament
testing of touch-pressure 4/6, CDT 4/6, cooling
discrimination 3/6, HP 5 2/6, and HP 0.5 2/6.
The sensitivities and specificities of the different
modalities of sensation are provided as a footnote
to Table 1.
Accuracy of QST Results Compared with Signs (NIS),
Symptoms (NSC), and Composite Nerve Conduction
Score (R5 NC nds £2.5th Percentile). An important
measure of accuracy of QSTs is the correlation of
QST results with measured continuous measures of
severity of signs, symptoms, and nerve conduction
assessed independently (Table 2). High ICC values
were obtained for all QSTs except for heat as pain
5 (HP 5) and HP 0.5 (threshold). Very high corre-
lations were found for both hand- and instrument-
administered stimuli and for modalities of vibration,
touch-pressure, cooling, and cooling discrimination,
and as compared to nerve conductions, neuropathy
signs (NIS), or neuropathy symptoms (NSC).
Lower ICC values were obtained for heat as pain
threshold (HP 0.5) or intensity (HP 5). The lower
correlation of heat as pain measures should not be
attributed to lower proficiency of the heat as pain
tests, because results are compared incorrectly with
Table 1. Raw Values of Quantitative Sensation Test (QST) Results (Mean and SD) and Signs (NIS), Symptoms (NSC) and Composite
Scores of Nerve Conduction (R5 NC nds) for Cl vs. NPhys Trial 5 Assessing Proficiency of QSTs.
Patients
Healthy subjects (n5 6)
Patients with diabetic
polyneuropathy (n56)
Parameter 1 2 3 4 5 6 7 8 9 10 11 12
VDT (JND)
(shaded if > 97.5th)
Mean 13.2 17.7 10.4 19.8 13.5 19.5 21.3 22.3 20.0 26.0 26.0 21.7
SD 1.3 1.9 0.9 0.9 0.9 1.0 1.2 0.6 3.5 0.0 0.0 1.2
Monofilament (JND)
(shaded if > 97.5th)
Mean 2.0 3.3 2.3 5.2 2.2 4.5 6.5 13.2 6.7 19.0 19.0 14.3
SD 2.0 2.1 1.9 2.5 1.9 2.2 2.0 1.6 0.8 0.0 0.0 2.3
CDT (JND)
(shaded if > 97.5th)
Mean 10.7 7.3 7.9 9.1 – 8.3 12.8 21.8 16.8 26.0 26.0 21.2
SD 2.6 2.5 1.1 1.7 – 2.7 4.3 2.2 5.5 0.0 0.0 2.5
Cooling Discrimination (JND)
(shaded if > 97.5th)
Mean 1.3 1.7 1.3 1.7 1.3 1.7 2.7 12.5 6.5 13.0 13.0 6.8
SD 0.5 0.5 0.5 1.0 0.5 0.8 1.6 0.5 2.1 0.0 0.0 2.0
HP:5 (JND)
(shaded if > 97.5th)
Mean 22.8 24.7 23.9 22.7 24.2 23.1 22.1 26.1 24.1 29.8 29.5 23.8
SD 0.5 1.1 0.5 0.5 1.0 1.5 0.6 2.7 0.7 0.4 0.8 0.4
HP:0.5 (JND)
(shaded if > 97.5th)
Mean 20.7 20.6 22.2 19.3 22.0 22.5 20.6 22.7 21.3 24.9 24.4 20.4
SD 0.7 1.3 0.4 1.3 0.6 1.4 0.8 1.7 1.5 1.6 1.8 1.4
NIS (pts)
(shaded if > 2 pts)
Raw 0 0 0 0 0 0 0 21 2 30 79 39
NSC (pts)
(shaded if > 1 pts)
Raw 0 0 0 0 0 0 1 3 1 6 9 6
R5 NC nds*
(shaded if < 2.5th)
Raw 3.5 3.1 1.7 1.2 20.1 21.8 28.1 29.3 212.2 212.9 214.2 215.1
Sensitivity and specificity (95% CIs) are: VDT, 91.7% (83.3%, 91.7%) and 83.3% (83.3%, 91.7%); Monofilament, 100.0% (100.0%, 100.0%) and 66.7%
(66.7%, 75.0%); CDT, 75.0% (66.7%, 83.3%) and 66.7% (65.0%, 66.7%); Cooling Discrimination, 100.0% (100.0%, 100.0%) and 58.4% (50.0%, 58.4%);
HP 5, 100.0% (100.0%, 100.0%) and 33.3% (33.3%, 50%); HP 0.5, 100.0% (83.3%, 100.0%) and 33.3% (16.7%, 50.0%). For sensitivity and specificity, R5
NC nds is used as an indication of abnormality. See text for an explanation of why sensitivities and specificities of HP 5 may be lower than other modalities
of sensations tested, i.e. different anatomical sites tested and possible difference in vulnerability of sensory nerve fibers in DSPN.
*R5 NC nds are mean values of measurable values of standard normal deviates from percentiles corrected for applicable variables obtained from the
RDNS-HS database of fibular nerve compound muscle action potential (fib CMAP), fibular motor nerve conduction velocity (fib MNCV), fibular distal latency
(fib MNDL), tibial MNDL, and sural sensory nerve action potential (sural SNAP) multiplied by 5. Abnormality of R5 NC nds was set at < 2.5th percentile
based on study of 330 healthy subjects in the RDNS-HS cohort with R5 NC nd values plotted on age.
Table 2. ICC of Mean Ranks* of 6 QST Tests with Ranks* of R5 NC nds, NIS, and NSC.
Parameter VDT (nd) Monofilament (JND) CDT (nd) Cooling Discrimination (JND) HP:5 (nd) HP:0.5 (nd)
R5 NC nds ICC (3,1) 0.83 0.88 0.74 0.85 0.49 0.41
95 % CI (0.54, 0.95) (0.66, 0.97) (0.36, 0.92) (0.58, 0.96) (20.05, 0.83) (20.14, 0.80)
NIS (pts) ICC (3,1) 0.85 0.9 0.88 0.93 0.7 0.5
95 % CI (0.59, 0.96) (0.72, 0.97) (0.66, 0.97) (0.78, 0.98) (0.28, 0.91) (20.04, 0.84)
NSC (pts) ICC (3,1) 0.88 0.93 0.87 0.95 0.58 0.44
95 % CI (0.67, 0.97) (0.80, 0.98) (0.64, 0.96) (0.84, 0.99) (0.08, 0.87) (20.11, 0.81)
*Ranks are the original rank divided by the number of non-missing patients.
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a less affected body site and to large fiber dysfunc-
tion expressed to a greater degree at a distal site.
Therefore the correlation of the heat as pain test
has not been adequately tested in this trial.
Intra- and Interobserver Differences of QST
Results. This information is provided in Table 3.
Using the Kappa (K) coefficient, a high degree of
intraobserver reproducibility was observed for
modalities of QSTs for each of the 3 technologists.
The median K coefficients for technologists 1, 2,
and 3 were 0.83, 0.92, and 1.00–all very high and
not significantly different among technologists.
Also, no significant interobserver difference was
observed for assessment of QST results (Table 3).
The bootstrap sample mean is 0.84 with a 95%
confidence interval of 0.71, 0.92.
Illustrating Body Distribution of Sensation Loss in
Symmetrical Length Dependent Sensorimotor
Polyneuropathy. For following course of weakness,
sensation loss, or autonomic deficit in therapeutic
trials, it may not be sufficient to score abnormality
at single anatomical sites; instead, the distributed
deficit may need to be tested. Use of too few exam-
ination sites might produce too large a floor (or
ceiling) effect for use in therapeutic trials. Consid-
ering assessment of QSTs for therapeutic trials a
preferred approach might be to assess distributed
sensation loss over the body surface area. To do
such an assessment thoroughly would require
excessive testing time. However, when the sensa-
tion loss is known to be symmetrical and length-
dependent, it is possible to arrive at the distribu-
tion of sensation loss by use of efficient algorithms
of testing. Using a specially designed computer
software program and with known threshold values
of the different distributed anatomical sites it is
possible to estimate the distribution of sensation
loss in a reasonable time period. The details of the
approach will be described elsewhere but are illus-
trated here for a patient with diabetic sensorimo-
tor polyneuropathy (Fig. 2).
DISCUSSION
The kind, severity, and body surface distribu-
tion of sensation decrease or heightened sensory
phenomena (e.g., positive neuropathic sensory
symptoms of “asleep numbness, prickling or stab-
bing, burning, or deep aching pain” or tactile or
thermal hyperalgesia) need to be assessed in clini-
cal medicine. Disorders with these manifestations
are common and are the cause of considerable
morbidity and high health care cost. While the
clinical neurologic examination is typically used to
assess these sensory phenomena, it is generally rec-
ognized that such assessment is frequently not
done or is not done well. It is difficult for physi-
cians using only hand-administered stimuli (cotton
wool, stick pins, vibration of a tuning fork, or dis-
placement of a digit) to reliably recognize
Table 3. Intra- and Inter-Observer QST Agreement in Cl vs. NPhys Trial 5.
n (%) of 12
Cochran Q test for
differences among
3 technologists
Day 1 Day 2 Day 1 Day 2
Parameter Technologist Normal Abnormal Normal Abnormal Q p Q p j p
VDT (JND) 1 6(50) 6(50) 5(41.67) 7(58.33) 2.00 0.37 1.00 0.61 0.83 0.0017
2 7(58.33) 5(41.67) 6(50) 6(50) 0.83 0.0017
3 7(58.33) 5(41.67) 6(50) 6(50) 0.50 0.0395
Monofilament (JND) 1 8(66.67) 4(33.33) 7(58.33) 5(41.67) -§ - 2.00 0.37 0.82 0.0019
2 8(66.67) 4(33.33) 8(66.67) 4(33.33) 1.00 0.0003
3 8(66.67) 4(33.33) 8(66.67) 4(33.33) 1.00 0.0003
CDT (JND)* 1 7(58.33) 5(41.67) 5(45.45) 6(54.55) 1.00 0.61 - - 0.46 0.0608
2 7(58.33) 5(41.67) 7(58.33) 5(41.67) 1.00 0.0003
3 6(50) 6(50) 7(58.33) 5(41.67) 0.83 0.0017
Cooling Discrimination (JND) 1 8(66.67) 4(33.33) 9(75) 3(25) 2.00 0.37 2.00 0.37 0.80 0.0023
2 9(75) 3(25) 8(66.67) 4(33.33) 0.80 0.0023
3 9(75) 3(25) 9(75) 3(25) 1.00 0.0003
HP 5 (JND) 1 9(75) 3(25) 9(75) 3(25) 2.00 0.37 2.00 0.37 1.00 0.0003
2 10(83.33) 2(16.67) 10(83.33) 2(16.67) 1.00 0.0003
3 10(83.33) 2(16.67) 10(83.33) 2(16.67) 1.00 0.0003
HP 0.5 (JND) 1† 9(75) 3(25) 9(75) 3(25) 4.50 0.11 2.67 0.26 1.00 0.0003
2 12(100) 0(0) 11(91.67) 1(8.33) 0.26 0.1448
3 9(75) 3(25) 9(75) 3(25) 1.00 0.0003
*One patient had faulty marking of test site, therefore was not included.
†0.5 was added to the count in each cell before kappa was calculated.
§Cochran Q test could not be computed.
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thresholds of sensation that may vary with anatomi-
cal site, age, gender, and anthropomorphic varia-
bles. It is an even greater problem to assess these
modalities of sensation over the surface of the
body and over time. While it is recognized that
physicians can achieve a high degree of proficiency
using simple hand-held instruments, one cannot
assume that physicians involved in therapeutic tri-
als will manifest a sufficient level of proficiency to
meet the high requirements of such trials. Usual
sensory testing is not standardized sufficiently, ref-
erenced, or proficient to be used confidently as a
primary outcome measure in therapeutic trials. In
comparison it is now possible to use highly standar-
dized QSTs that provide standardized and refer-
enced smart QSTs by which to test sensation loss
among medical centers and with time.
For QSTs to meet the need for use in therapeu-
tic trials, stimuli should be appropriately chosen,
should be of known waveform and magnitude, and
stimulus magnitude should increase exponentially
in steps from very small to very large to be suitable
for neurosensory testing. Validated algorithms of
testing and threshold finding should be used. Ref-
erence values corrected for applicable variables
should be available for tested anatomical sites. For
therapeutic trials, it would be desirable for all QST
events to be programmed so that tests would be
given and assessed by exactly the same procedures
and be expressed with comparison to standard ref-
erence values corrected for applicable variables. In
this trial, although both hand- and instrument-
testing was used, all 6 QSTs fulfilled the standard
criteria listed above, including instruction, hand-
administered stimuli, and overall conduct of tests.
For multicenter trials of sensorimotor polyneu-
ropathy, is assessment of sensation and its body sur-
face distribution necessary? Would it suffice to
assess only surrogate measures of sensation loss,
e.g., attributes of nerve conduction of sensory fibers
or of quantitative measures of epidermal nerve
fibers? While this might suffice for some trials, for
many other trials actual assessment of sensation loss
is needed, because nerve conduction abnormality
and epidermal nerve fiber counts may not repre-
sent the kind, severity, and distribution of sensation
loss and have major floor (ceiling) effects. Also, the
number of times that tissue can be biopsied is lim-
ited. Additionally, histologic tests are more detailed,
time consuming, and expensive than QSTs.
This trial provides strong proof of concept that
the highly standardized and referenced QSTs
assessed here provided accurate information about
touch-pressure, vibration, cooling, cooling discrimi-
nation, and heat as pain loss without intra- and
intertest differences. The results suggest that if the
tests were done in exactly the same way using the
same reference values corrected for applicable vari-
ables, similar good results would be possible when
done at other medical centers, assuming that tech-
nologist performance and patient responses were
also the same. The good test performance
observed here probably relates to: (1) the use of
highly standardized stimuli and null stimuli, rang-
ing from very small to very large in exponential
steps; (2) use of validated algorithms of testing
and finding threshold (which does not arrive at
spurious results simply because insufficient replica-
tions are assessed); (3) use of reference values cor-
rected for applicable variables of anatomical site,
age, and anthropomorphic variables; and (4) han-
dling of all aspects of testing, estimation of thresh-
old, analysis of results, and printing out of results
using computer technology. Obviously, the impor-
tant role of technologists in performance of QST
cannot be minimized. But use of the QST technol-
ogy explained in these studies minimizes the tasks
that technologists must perform to a minimum.
FIGURE 2. An illustration of smart QST of body surface areas
to assess distributed sensation loss of touch pressure and heat
as pain 5 (of 1–10) in a patient with transthyretin amyloid
polyneuropathy.
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They provide instruction, observe patient alertness
and cooperation, correctly administer the test, and
perform related activities. It goes without saying
that the QSTs should be administered only to
cooperating patients.
Which modalities of sensation should be used for
therapeutic trials or longitudinal follow-up
of patients with sensorimotor polyneuropathy?
Although this question was not addressed in this trial,
several possibilities could be considered. It seems
unlikely that users would want to include all of the
QSTs studied here, especially knowing that several or
multiple anatomical sites might need to be tested.
Thus, for a trial of polyneuropathy in which large
fibers are mainly involved (e.g., a trial of spinocere-
bellar degeneration), tests of touch-pressure or vibra-
tion might be suitable. In trials in which small fibers
are affected preferentially (e.g., atypical small fiber
polyneuropathy associated with diabetes mellitus or
Fabry disease), heat as pain or cooling detection
threshold might be tested. In transthyretin amyloid
polyneuropathy (ATTR-PN) with involvement of
both small and large sensory fibers, a measure of
both large (touch-pressure) and small (heat as pain)
sensory fiber involvement might be tested.
To make multiple anatomical site testing possi-
ble in a reasonable period of time it is important
to use highly efficient algorithms of testing as illus-
trated in Figure 2. The possible time saving with
the use of this algorithm comes from: (1) testing
only 1 side (because the polyneuropathy is symmet-
rical); (2) beginning at a suitable length-dependent
site, e.g., at lateral leg or volar forearm, and testing
in both or either proximal or distal directions
depending on response; (3) not taking the extra
time needed to estimate threshold precisely, testing
only to values 99th, <95th or 95th– <99th; (4)
having previously determined the percentile levels
of the 95th and 99th percentile for 10 anatomical
sites; and (5) using computer software to manage
all testing procedures, decision making, and print-
out of results so that technologists can reliably
instruct, observe, hand-administer monofilament
stimuli, and enter test responses.
The decision about which modality of sensation
to use in multicenter trials might also depend on
measures of sensitivity and specificity and correlation
with surrogate measures of sensation loss. By these
criteria, touch-pressure, vibration, and cooling
thresholds performed at very high levels in the pres-
ent trial. Heat as pain performed at a lower level,
but its performance was not tested adequately. Large
fiber sensory tests are compared appropriately to
attributes of nerve conduction (both large fiber
functions), but heat as pain (a small fiber function)
should be compared with another measurement
than nerve conduction (as done here).
The high degree of proficiency demonstrated
in this trial was not unexpected, because previous
trials of QST, in some cases using very similar tech-
nologies, provided strong evidence of test–retest
reproducibility3–5,21–27 and in a few trials of inter-
observer reproducibility also.23,28
What uses should be made of the proficient
smart QSTs described here? While this question
was not a focus of these studies, some possibilities
come to mind. These approaches are being used
for the study of metabolic and inherited polyneu-
ropathy. Assessment of the course of sensation loss
could be an important outcome measure in dia-
betic sensorimotor polyneuropathy. The QST BS 20
TP and HP5 approach might reasonably be used
for conduct of therapeutic trials of transthyretin
amyloid polyneuropathy. For individual patients
with sensorimotor polyneuropathy on a treatment
trial in medical practice, QSTs evaluated here
might be used to help provide information on effi-
cacy of treatment.
In this trial, only loss of sensation was assessed
without assessment of aberrant sensory phenom-
enon such as positive neuropathy sensory symp-
toms and measured tactile or thermal hyperalgesia.
Although the latter 2 phenomena could be
assessed by QST, they were not studied in this trial.
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